Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data to Get $1.5M from Sale of Non-core Assets

NEW YORK (GenomeWeb News) – Clinical Data today said that it would receive $1.5 million from the sale of substantially all of the property and equipment at Avalon Pharmaceuticals' Germantown, Md., facility.

The Newton, Mass.-based drug and pharmacogenomic assay developer acquired Avalon earlier this year for $10 million, providing Clinical Data with a pipeline of oncology biomarkers and a biomarker discovery platform that will be used to identify diagnostic and therapeutic candidates.

Today, Clinical Data sold the non-core assets from that purchase to Intrexon, a Blacksburg, Va.-based genetic engineering firm, for $1.5 million in cash plus the assumption of certain liabilities. Clinical Data also said that it expects to realize annual cost savings of $4 million to 45 million associated with the transaction.

Intrexon said that the Maryland site will become the home of its human therapeutics division.

"This transaction is another step forward in our strategy to allocate our resources to Clinical Data's late-stage drug development programs and other early-stage priority programs, while continuing to divest any assets that are not core to this mission," Drew Fromkin, Clinical Data's President and CEO, said in a statement.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.